1. Awad IA, Carter LP, Spetzler RF, Medina M, Williams FC Jr. Clinical vasospasm after subarachnoid hemorrhage: response to hypervolemic hemodilution and arterial hypertension. Stroke. 1987 Mar-Apr;18(2):365-372;
2. Barth M, Capelle HH, Weidauer S, Weiss C, Münch E, Thomé C, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke. 2007 2;38(2):330-336;
3. Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD, Ogilvy CS, Carter BS, et al. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol. 2004 5;25(5):819-826;
4. Bayer HealthCare: Important drug warning. 2006. 2.
6. Biondi A, Ricciardi GK, Puybasset L, Abdennour L, Longo M, Chiras J, et al. Intra-arterial nimodipine for the treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage: preliminary results. AJNR Am J Neuroradiol. 2004 Jun-Jul;25(6):1067-1076;
7. Chan PD, Findlay JM, Vollrath B, Cook DA, Grace M, Chen MH, et al. Pharmacological and morphological effects of in vitro transluminal balloon angioplasty on normal and vasospastic canine basilar arteries. J Neurosurg. 1995 9;83(3):522-530;
9. Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage: Part I: Incidence and effects. J Clin Neurosci. 1994 1;1(1):19-26;
10. Elliott JP, Newell DW, Lam DJ, Eskridge JM, Douville CM, Le Roux PD, et al. Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 1998 2;88(2):277-284;
12. Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology. 1998 4;50(4):876-883;
13. Findlay JM, Nisar J, Darsaut T. Cerebral vasospasm: A review. Can J Neurol Sci. 2016 1;43(1):15-32;
14. Firat MM, Gelebek V, Orer HS, Belen D, Firat AK, Balkanci F. Selective intraarterial nimodipine treatment in an experimental subarachnoid hemorrhage model. AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1357-1362;
15. Firlik KS, Kaufmann AM, Firlik AD, Jungreis CA, Yonas H. Intra-arterial papaverine for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Surg Neurol. 1999 1;51(1):66-74;
17. Hoh BL, Ogilvy CS. Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intraarterial papaverine, and intra-arterial nicardipine. Neurosurg Clin N Am. 2005 7;16(3):501-516; vi
18. Horn J, Limburg M. Calcium antagonists for ischemic stroke: a systematic review. Stroke. 2001 2;32(2):570-576;
19. Kaku Y, Yonekawa Y, Tsukahara T, Kazekawa K. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 1992 12;77(6):842-847;
20. Kassell NF, Helm G, Simmons N, Phillips CD, Cail WS. Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg. 1992 12;77(6):848-852;
21. Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL. The international cooperative study on the timing of aneurysm surgery. Part 1: overall management results. J Neurosurg. 1990 7;73(1):18-36;
22. Katoh H, Shima K, Shimizu A, Takiguchi H, Miyazawa T, Umezawa H, et al. Clinical evaluation of the effect of percutaneous transluminal angioplasty and intra-arterial papaverine infusion for the treatment of vasospasm following aneurysmal subarchnoid hemorrhage. Neurol Res. 1999 3;21(2):195-203;
24. Kirkpatrick PJ, Turner CL, Smith C, Hutchinson PJ, Murray GD. STASH Collaborators. Simvastatin in aneurysmal subarachnoid hemorrhage (STASH): a multicentre randomized phase 3 trial. Lancet Neurol. 2014 7;13(7):666-675;
25. Kobayashi H, Ide H, Aradachi H, Arai Y, Handa Y, Kubora T. Histological studies of intracranial vessels in primates following transluminal angioplasty for vasospasm. J Neurosurg. 1993 3;78(3):481-486;
26. Kuwayama A, Zervas NT, Shintani A, Pickren KS. Papaverine hydrochloride and experimental hemorrhagic cerebral arterial spasm. Stroke. 1972 Jan-Feb;3(1):27-33;
27. Kwak R, Niizuma H, Ohi T, Suzuki J. Angiographic study of cerebral vasospasm following rupture of intracranial aneurysms: Part 1. Time of the appearance. Surg Neurol. 1979 4;11(4):257-262;
29. Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000 2;31(2):383-391;
30. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. Clazosentan toovercome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1) : randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008 11;39(11):3015-3021;
31. Mindea SA, Yang BP, Bendok BR, Miller JW, Batjer HH. Endovascular treatment strategies for cerebral vasospasm. Neurosurg Focus. 2006 9;21(3):E13.
32. Murai Y, Kominami S, Kobayashi S, Mizunari T, Teramoto A. The long-term effects of transluminal balloonangioplasty for vasospasms after subarachnoid hemorrhage: analyses of cerebral blood flow and reactivity. Surg Neurol. 2005 8;64(2):122-126; discussion 127.
33. Newell DW, Eskridge JM, Mayberg MR, Grady MS, Winn HR. Angioplasty for the treatment of symptomatic vasospasm following subarachnoid hemorrhage. J Neurosurg. 1989 11;71(5 Pt 1):654-660;
34. Ogata M, Marshall BM, Lougheed WM. Observation on the effects of intrathecal papaverine in experimental vasospasm. J Neurosurg. 1973 1;38(1):20-25;
35. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997 3;95(5):1126-1131;
36. Peroutka SJ, Allen GS. Calcium channel antagonist binding sites labeled by 3H-nimodipine in human brain. J Neurosurg. 1983 12;59(6):933-937;
37. Pisani A, Calabresi P, Tozzi A, D'Angelo V, Bernardi G. L-type Ca2+ channel blockers attenuate electrical changes and Ca2+ rise induced by oxygen/glucose deprivation in cortical neurons. Stroke. 1998 1;29(1):196-201;
38. Rosenwasser RH, Armonda RA, Thomas JE, Benitez RP, Gannon PM, Harrop J. Therapeutic modalities for the management of cerebral vasospasm: timing of endovascular options. Neurosurgery. 1999 5;44(5):975-979;
39. Sayama CM, Liu JK, Couldwell WT. Update on endovascular therapies for cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurosurg Focus. 2006 9;21(3):E12.
41. Schuknecht B. Endovascular treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl. 2005 94:47-51;
42. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM. Efficacy and safety of the endothelinA/B receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg. 2000 12;93(6):992-997;
43. Stippler M, Crago E, Levy EI, Kerr ME, Yonas H, Horowitz MB, et al. Magnesium infusion for vasospasm prophylaxis after subarachnoid hemorrhage. J Neurosurg. 2006 11;105(5):723-729;
44. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med. 2006 1;354(4):387-396;
46. Vajkoczy P, Meyer B, Weidauer S, Raabe A. Thome C. Ringel F, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage; results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg. 2005 7;103(1):9-17;
47. Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002 3;96(3):510-514;